[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368187-105":59,"doc-detail-368187-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","long-term-intracranial-progression-free-survival-in-lung-cancer-brain-metastases-extended-beyond-50-months-with-gubenxiaoyi-formula-gbxy-a-groundbreaking-case-study","Long-Term Intracranial Progression-Free Survival in Lung Cancer Brain Metastases Extended Beyond 50 Months with Gubenxiaoyi Formula (GBXY) - A Groundbreaking Case Study","","Brain metastases in lung cancer patients are common and carry poor prognoses, yet standard regimens have limited effectiveness in improving intracranial progression-free survival (IPFS). Traditional Chinese medicine has shown benefits for quality of life and prognosis in lung cancer, but its role in brain metastases is rarely reported. This case documents a middle-aged woman with progressive disease after standard local surgeries, stereotactic radiotherapy, chemotherapy, and EGFR-TKIs. After treatment with gubenxiaoyi (GBXY) for 55 months, intracranial lesions decreased by about 50%, with IPFS and cognitive deterioration-free survival extending beyond 50 months.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-intracranial-progression-free-survival-in-lung-cancer-brain-metastases-extended-beyond-50-months-with-gubenxiaoyi-formula-gbxy-a-groundbreaking-case-study/368187/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-intracranial-progression-free-survival-in-lung-cancer-brain-metastases-extended-beyond-50-months-with-gubenxiaoyi-formula-gbxy-a-groundbreaking-case-study/368187.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is intracranial progression-free survival (IPFS) important in lung cancer brain metastases?","Question",{"text":112,"@type":113},"Brain metastases are associated with poor prognosis, and standard regimens have limited ability to improve intracranial progression-free survival. This makes extending IPFS clinically significant.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatments did the patient receive before starting GBXY?",{"text":117,"@type":113},"The patient underwent two local surgeries for cerebellar lesions, stereotactic radiotherapy, chemotherapy, and EGFR-TKIs. Her condition was assessed as progressive after standard treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were observed after GBXY treatment?",{"text":121,"@type":113},"After 55 months of GBXY therapy, intracranial lesions were reduced by about 50%. Intracranial progression-free survival and cognitive deterioration-free survival both exceeded 50 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368187,1790899577,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Long-Term Intracranial Progression-Free Survival in Lung Cancer Brain Metastases Extended Beyond 50 Months with Gubenxiaoyi Formula (GBXY):  \nA Groundbreaking Case Study  \nIntegrative Cancer Therapies Volume 24: 1–9  \n© The Author(s) 2025  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15347354241313334](DOI: 10.1177/15347354241313334)[ ](DOI: 10.1177/15347354241313334)[journals.sagepub.com/home/ict](journals.sagepub.com/home/ict)  \nZhengzheng Yang, MD 1*, Haiming Li, MM 1*, Lei Chen, MD 1*, Shujiao Li, MD2*, Dong Chen, MD 1, Taicheng Lu, MD3, Tongjing Ding, MD 1, Ruiyang Han, MM 1, Peiyu Cheng, MD 1, and Xiaomin Wang, MD 1  \nAbstract  \nBackground:The prevalence of brain metastases (BM) in lung cancer patients is notably high and is associated with poor prognoses. The efficacy of standard treatment regimens in improving intracranial progression-free survival (IPFS) for lung cancer BM is markedly limited. While traditional Chinese medicine (TCM) has been effective in enhancing the quality of life and prognosis of lung cancer patients, its efficacy in treating BM remains unreported. Case presentation: Here, we present a case of a middle-aged female with lung cancer BM, whose condition was assessed as progressive post-standard treatment including two local surgeries (both involving resection of cerebellar space-occupying lesions), stereotactic radiotherapy, chemotherapy and EGFR-TKIs. Subsequently, she underwent treatment with the traditional Chinese herbal formula gubenxiaoyi (GBXY). The patient was treated with GBXY for a total duration of 55 months. After treatment, a significant reduction of about 50% in intracranial lesions was observed, accompanied by an extension of both Intracranial Progression-Free Survival (IPFS) and Cognitive Deterioration-Free Survival (CDFS) exceeding 50 months. Conclusion: These results demonstrate that in patients with lung cancer brain metastases (BM) unresponsive to standard treatments, GBXY not only has the potential to effectively prolong IPFS and decelerate cognitive decline, but may also contribute to a reduction in intracranial tumor burden. This suggests that GBXY could be a promising therapeutic option that warrants further investigation.  \nKeywords  \nlung cancer brain metastases, traditional Chinese medicine, intracranial progression-free survival, cognitive-deteriorationfree survival  \nSubmitted September 5, 2024; revised November 11, 2024; accepted December 30, 2024  \nIntroduction  \nBrain metastases (BMs) manifest with notable frequency in the patient population grappling with lung cancer. Comprehensive studies delineate that the primary culprits of brain metastasis encompass melanoma, accounting for 28.2%, followed by lung cancer at a rate of 20%-30%, and renal cancer contributing to 10% of such cases.1 Among individuals afflicted with non-small cell lung cancer (NSCLC), about 10.4% will eventually develop BMs, with this proportion increasing to 25% in stage IV patients.2 The dire prognosis associated with lung cancer is closely linked to the presence of BMs. Studies demonstrate that NSCLC patients with untreated BMs have a median survival of approximately  \n1 Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China  \n2Eye Hospital China Academy of Chinese Medical Sciences, Beijing, China 3Beijing University of Chinese Medicine, Beijing, China  \n*These authors contributed equally to this work.  \nCorresponding Authors:  \nPeiyu Cheng, Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Houjie of the Art Museum, Dongcheng District, Beijing 100010, China.  \nEmail: [cpy2599@126.com](cpy2599@126.com)  \nXiaomin Wang, Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Houjie of the Art Museum, Dongcheng District, Beijing 1","cbCairjUREsFs9eE","https://ap.wps.com/l/cbCairjUREsFs9eE","pdf",1094119,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why is intracranial progression-free survival (IPFS) important in lung cancer brain metastases?\",\"answer\":\"Brain metastases are associated with poor prognosis, and standard regimens have limited ability to improve intracranial progression-free survival. This makes extending IPFS clinically significant.\"},{\"question\":\"What treatments did the patient receive before starting GBXY?\",\"answer\":\"The patient underwent two local surgeries for cerebellar lesions, stereotactic radiotherapy, chemotherapy, and EGFR-TKIs. Her condition was assessed as progressive after standard treatment.\"},{\"question\":\"What outcomes were observed after GBXY treatment?\",\"answer\":\"After 55 months of GBXY therapy, intracranial lesions were reduced by about 50%. Intracranial progression-free survival and cognitive deterioration-free survival both exceeded 50 months.\"}]","Long-Term Intracranial Progression-Free Survival in Lung Cancer Brain Metastases Extended Beyond 50 Months with Gubenxiaoyi Formula (GBXY) - A Groundbreaking Case Study | PDF",1790175497,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/336e464c374c6418a6898bdcee77f120.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e68524dfbb28f18e4ef18017eb64940.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec3552c702718c9b823d581beaafb129.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2be571304301b751446ece49ee2c83f2.webp",980,1272]